Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab Phase 1 Study in Healthy Subjects with Malaria Challenge
NCT04327310Phase 1Withdrawn
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in Plasmodium falciparum malaria comparing Meplazumab with Placebo (2 arms). Primary endpoints: Presence of Anti-antibodies and Adverse events / serious adverse events. Planned start Mar 2023; status: withdrawn.
02
Drugs
meplazumab
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT04327310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327310.